Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor
Benjamin Lerman(Children's Hospital of Philadelphia), Rochelle Bagatell(Children's Hospital of Philadelphia), Rajen Mody(University of Michigan–Ann Arbor), Yimei Li(Children's Hospital of Philadelphia), Aeesha Ranavaya(Cincinnati Children's Hospital Medical Center), Michelle Choe(Baylor College of Medicine), Keri A. Streby(Nationwide Children's Hospital), Daniel A. Morgenstern(University of Toronto), Arhanti Sadanand(Emory University), Ami V. Desai(University of Chicago Medical Center), Brian Weiss(Cincinnati Children's Hospital Medical Center), Sara M. Federico(St. Jude Children's Research Hospital), Meaghan Granger(Cook Children's Medical Center), Margaret E. Macy(Morgan Adams Foundation), Jennifer H. Foster(Texas Children's Hospital), Rachel N. Zeno(Nationwide Children's Hospital), Thomas F. Cash(Emory University), Suzanne Shusterman(Dana-Farber Cancer Institute), Sahr Yazdani(University of Michigan), Navin Pinto(Seattle Children's Hospital), Cecilia Carlowicz(Children's Hospital of Philadelphia), Margarida Rafael(Hospital Sant Joan de Déu Barcelona), Katherine Somers(Cincinnati Children's Hospital Medical Center)
Cited by 42
Related Papers
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
|JAMA|2015|416
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial
|The Lancet Oncology|2019|341